GeneDx Q2 Earnings Call Highlights
MarketBeat
GeneDx (NASDAQ:WGS) reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability one quarter earlier than previously expected, while maintainin
NASDAQ:WGS